Houlden H, Lincoln S, Farrer M, Cleland PG, Hardy J, Orrell RW (2003) Compound heterozygous
PANK2 mutations confirm HARP and Hallervorden–Spatz syndromes are allelic. Neurology 61:
1423–1426.
Johnson MA, Kuo YM, Westaway SK, et al (2004) Mitochondrial localization of human PANK2 and
hypotheses of secondary iron accumulation in pantothenate kinase-associated neurodegeneration.
Ann NY Acad Sci 1012: 282–298.
Kotzbauer PT, Truax AC, Trojanowski JQ, Lee VM (2005) Altered neuronal mitochondrial coenzyme
A synthesis in neurodegeneration with brain iron accumulation caused by abnormal processing,
stability, and catalytic activity of mutant pantothenate kinase 2. J Neurosci 25: 689–698.
Kuo YM, Duncan JL, Westaway SK, et al (2005) Deficiency of pantothenate kinase 2 (Pank2) in mice
leads to retinal degeneration and azoospermia. Hum Mol Genet 14: 49–57.
Min KT, Benzer S (1999) Preventing neurodegeneration in the Drosophila mutant bubblegum. Science
284: 1985–1988.
Polich J, Gloria R (2001) Cognitive effects of a Ginkgo biloba/vinpocetine compound in normal adults:
systematic assessment of perception, attention and memory. Hum Psychopharmacol 16: 409–416.
Quaranta L, Bettelli S, Uva MG, Semeraro F, Turano R, Gandolfo E (2003) Effect of Ginkgo biloba
extract on preexisting visual field damage in normal tension glaucoma. Ophthalmology 110: 359–
362.
Tarnopolsky MA, Beal MF (2001) Potential for creatine and other therapies targeting cellular energy
dysfunction in neurological disorders. Ann Neurol 49: 561–574.
Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ (2001) A novel pantothenate
kinase gene (PANK2) is defective in Hallervorden–Spatz syndrome. Nature Genetice 28: 345–349.
